Offer of methods for minimizing key investment risks of “R-Pharm” JSC
https://doi.org/10.32686/1812-5220-2020-17-1-58-67
Abstract
The article is devoted to the assessment of potential investment risks of the pharmaceutical company “R-Pharm” JSC with the aim of identifying the highest priority risks and developing methods for minimizing them. The relevance of the study is determined by the fact that the pharmaceutical business is characterized by a high degree of social orientation and annually invests $ 140 billion in the development of production and research, which determines the need for a risk-based approach to ensure the return on investment. The subject of this article is the investment risks of pharmaceutical companies, and the subject of research is the domestic pharmaceutical company “R-Pharm”. In order to assess the potential investment risks of “R-Pharm” JSC, the authors used elements of simulation modeling and system analysis. The proposed methods to minimize key investment risks are aimed at improving the efficiency of investment activities and is recommended as an element of the strategic planning of the company.
About the Authors
N. A. Kabanova
Financial University under Government of the Russian Federation
Russian Federation
Russian Federation
Natalya A. Kabanova
105187, Moscow, Shcherbakovskaya str., b. 38
I. K. Alekseeva
Financial University under Government of the Russian Federation
Russian Federation
Russian Federation
Irina K. Alekseeva
105187, Moscow, Shcherbakovskaya str., b. 38
References
1. The Code of the Russian Federation on administrative offenses of December 30, 2001 № 195-ФЗ // Russian newspaper. No 256, 12.31.2001. (Russia).
2. Federal Law dated 12.04.2010 № 61-ФЗ On the Circulation of Medicines // Rossiyskaya Gazeta, № 78. 04.14.2010. (Russia).
3. Federal law dated 05.04.2013 № 44-ФЗ “On the contract system in the field of procurement of goods, work, services for providing state and municipal needs” // Rossiyskaya Gazeta. № 80. 04.12.2013. (Russia).
4. Methodological recommendations for assessing the effectiveness of investment projects” (approved by the Ministry of Economy of the Russian Federation, Ministry of Finance of the Russian Federation, Gosstroy of the Russian Federation 06/21/1999 № VK 477). M.: Economics, 2000. (Russia).
5. Sozaeva D.A. Risk Management: Approaches, Models, Methodologies // Issues of Risk Analysis. Vol. 13. 2016. № 4. P. 6—20. (Russia). https://doi.org/10.32686/18125220-2016-13-4-6-20
6. Falin G. I. Risk analysis using the Monte Carlo method // Risk Management. 2017. № 1 (Russia).
7. Tsamutali S. A. Real Investments Risks Assessment // Economics. Taxes. Right. 2013. № 4. P. 32—37 (Russia).
8. Analytical review of the market for tender purchases of medicines following the results of 2018. URL: https: //dsm.ru/news/632/ (Date of access: 10.15.2019).
9. High-tech medicines: from development to implementation in clinical practice. URL:http://www.ravnoepravo.ru/fileadmin/user_upload/2016/forumIX/Vorozheykina.pdf (Date of access: 10.15.2019).
10. Medicines were selected for HIV. URL: https://yandex.com/turbo?text=https%3A%2F%2Fwww.kommersant.ru%2Fdoc%2F3841558 (Date of access: 10.15.2019).
11. The prosecutor's office of the Republic of Khakassia. A verdict in a criminal case against the territorial manager of one of the largest pharmaceutical companies for giving a bribe to an official. URL: https:www.genproc.gov.ru/smi/news/genproc/news-1592558/ (Date of access: 10.15.2019).
12. The Russian pharmaceutical "R-Farm" sold 10% its shares in Japanese Mitsui&Co. URL: https://tass.ru/ekonomika/4651733 (Date of access: 10.15.2019).
13. Russian Investment Forum Sochi 2019. The results of the forum. URL: https://rusinvestforum.org/news/rossijskij-investitsionnyj-forum-sochi-2019-itogi-rabotyforuma/ (Date of access: 10.15.2019).
14. RBV Capital Fund sells a portfolio company Bonti pharmaceutical manufacturer Allergan. URL: http://r-pharm.com/en/press-center/news/388 (Date of access: 15.10.2019)
15. What is the difference between domestic and imported drugs. URL: https://primechaniya.ru/home/news/13496/chem_na_samom_dele_otlichayutsya_otechestvennye_i_importnye_lekarstva (Date of access: 15.10.2019)
16. Deloitte: Government Regulation: Barriers or Incentives for Market Development? URL: https://www2.deloitte.com/content/dam/Deloitte/ru/Documents/life-sciences-healthcare/russian/russian-pharmaceutical-market-trends-2019.pdf (Date of access: 15.10.2019)
17. KPMG: How to compete and win in a world with biosimilars URL:https://home.kpmg/content/dam/kpmg/pdf/2015/10/world-of-biosimilars.pdf (Date of access: 15.10.2019).
Review
For citations:
Kabanova N.A., Alekseeva I.K. Offer of methods for minimizing key investment risks of “R-Pharm” JSC. Issues of Risk Analysis. 2020;17(1):58-67. (In Russ.) https://doi.org/10.32686/1812-5220-2020-17-1-58-67
Views:
1018
Email this article 